Table 2.
Studies calculating the cost of adverse drug events, clinical data
| N° | First author (year) (ref) | Country | Clinical area | Study design | Number of patients | Type of ADE | Population Settings | Suspected drug(s) |
|---|---|---|---|---|---|---|---|---|
| 1 | Katsuno et al. (2021) [19] | Japan | Inpatients and outpatients |
- observational - monocentric - retrospective |
359 | ADE | Patient aged > 1 year | All (except experimental drugs) |
| 2 | Trumbo et al. (2021) [8] | USA | Inpatients and outpatients |
Pharmacovigilance database - observational - multicentric - retrospective |
NK | ADE | All patients | Intravenous iron |
| 3 | Iwasaki et al. (2021) [18] | Japan | Inpatients (tertiary care hospital) |
- observational - multicentric - retrospective |
907 | Preventable ADE | Patients < 15 years and hospitalised in any unit and patients over 15 years old hospitalised in paediatric units | All prescribed medication |
| 4 | Tissot et al. (2021) [9] | France | Inpatients and outpatients |
Pharmacovigilance database - observational - multicentric - retrospective |
1185 | Serious ADR | All patients except patients with serious congenital anomalies related | All |
| 5 | Maity et al. (2021) [10] | Canada | Inpatients |
Pharmacovigilance database - observational - multicentric - retrospective |
63 069 | ADR | All patients | Remicad® and Humira® (biosimilars were not included) |
| 6 | Knight et al. (2019) [11] | South Africa | Inpatients (tertiary care hospital) |
- observational - monocentric - retrospective |
89 | ADR | All patients with drug sensitive tuberculosis with a suspected cutaneous adverse drug reaction to first line anti-tuberculosis drugs | First line anti-tuberculosis drugs |
| 7 | Boostani et al. (2019) [20] | Iran | Inpatients (tertiary care hospital / internal medicine unit) |
- observational - monocentric - prospective |
100 | ME | Patients hospitalised in internal medicine ward | All |
| 8 | Riaz et al. (2019) [16] | USA | Inpatients (tertiary care hospital) |
- observational - multicentric - retrospective |
3 832 322 | ADE | Age 65 and above | All |
| 9 | Beck et al. (2019) [12] | USA | Inpatients (emergency room and tertiary care) |
- observational - monocentric - retrospective |
430 | ADR | Patients under 21 | Antibiotics |
| 10 | Lee et al. (2019) [21] | Korea | Inpatients (emergency room and tertiary care) |
- observational - multicentric - retrospective |
903 | ADR | All patients | All |
| 11 | Liao et al. (2019) [17] | Taiwan | Inpatients (tertiary care hospital) |
- observational - monocentric - retrospective |
2 393 | ADR | Age 65 and above | All |
| 12 | Pok et al. (2018) [14] | Malaysia | Inpatients (tertiary care hospital/ rheumatology unit) |
- observational - multicentric - retrospective |
634 | ADE | Patient hospitalised in the rheumatology department with osteoarthritis or rheumatoid arthritis | NSAID |
| 13 | Schnippel et al. (2018) [13] | South Africa | Inpatients |
- observational - multicentric - retrospective |
12 527 | ADR | Multi drugs resistant (+ rifampicin) tuberculosis patients | Drugs used in rifampicin-resistant tuberculosis |
| 14 | Shafi et al. (2018) [15] | USA | Inpatients (tertiary care hospital/ Surgery and endoscopy unit) |
- observational - multicentric - retrospective |
135 379 | ADE | Age 18 and above (patients having surgery or endoscopy) | Opioids |
| 15 | Kurle et al. (2018) [22] | India | Inpatients (tertiary care hospital / dermatology unit) |
- observational - monocentric - prospective |
55 | ADR | All patients except patients using alternative therapies | All |
| 16 | Slight et al. (2018) [23] | USA | Inpatients (tertiary care hospital) |
- observational - monocentric - retrospective |
40 990 | Preventable ADE | All patients | All |
| 17 | Gyllensten et al. (2017) [24] | Sweden | Inpatients and outpatients |
- observational - multicentric - retrospective |
4 970 | ADE | Age 18 and above and living in the Östergötland county, Sweden | All |
| 18 | Natanaelsson et al. (2017) [25] | Sweden | Inpatients and outpatients |
- observational - multicentric - retrospective |
5 025 | ADE | Age 18 and above and living in the Östergötland county, Sweden | All |
| 19 | McCarthy Jr. et al. (2017) [26] | USA | Inpatients (tertiary care hospital) |
- observational - monocentric - retrospective |
3 521 | ADE | All patients | All |
| 20 | Spector et al. (2017) [27] | USA | Inpatients (tertiary care hospital) |
- observational - multicentric - retrospective |
85 338 | ADE | Age 18 and above | Anticoagulants and Hypoglycaemic agents |